If you have been reading about Mod GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
An entrée or main course, typically full meals consisting of preserved and nonperishable precooked meat, vegetables, legumes, grains, rice, or staple foods; dehydrated soup or broth may also be offered, often in the form of bouillon cubes Side dishes or appetizers such as crackers or biscuits, spreads (commonly cheese spread, peanut butter, jam or jelly, chocolate spread, or pâté), pickles, or preservable salad (usually potato salad, tuna salad, or fruit salad) Desserts or snacks such as candy, chocolate, dried fruits, nuts, cookies, cakes, pastries, cereal bars, or energy bars Drink mixes, commonly juice, powdered milk, instant coffee, instant tea, hot chocolate, energy drinks, protein drinks, or soft drinks Food supplements such as condiments, chewing gum, dietary supplements, and water purification tablets Tableware, typically mess kits and eating utensils (usually a single multipurpose utensil like a spoon, spork, chopsticks, or lusikkahaarukka) Additional items provided for personnel to use for themselves, such as multipurpose paper, napkins or tissue paper, toilet paper, matches, cigarettes (historically), and solid fuel Field rations may come in different varieties, or carry multiple meals, for breakfast, lunch, dinner, or supper. Vegetarian, vegan, and religious diet variants may be available if a military's demographics necessitate them.
== See also == Gladys Boyd, paediatrician, pioneer in the treatment of juvenile diabetes. Charles Best, co-discoverer of insulin. Elizabeth Hughes Gossett, a notable early recipient of insulin. Frederick Banting, co-discoverer of insulin. Islets of Langerhans Pancreas James D. Havens, first American to receive insulin from Toronto.
== Function == Actin's primary role in the cell is to form linear polymers called microfilaments that serve various functions in the cell's structure, trafficking networks, migration, and replication. The multifaceted role of actin relies on a few of the microfilaments' properties: First, the formation of actin filaments is reversible, and their function often involves undergoing rapid polymerization and depolymerization. Second, microfilaments are polarized – i.e. the two ends of a filament are distinct from one another. Third, actin filaments can bind to many other proteins, which together help modify and organize microfilaments for their diverse functions. In most cells actin filaments form larger-scale networks which are essential for many key functions:
Sources: en.wikipedia.org
=== Ion implantation === Accelerating carbon ions inside an electrical field into a semiconductor made of thin nickel films on a substrate of SiO2/Si, creates a wafer-scale (4 inches (100 mm)) wrinkle/tear/residue-free graphene layer at a relatively low temperature of 500 °C.
==== Approved topical medicine ==== In the European Union, a prescription gel containing birch bark extract (commercial name Episalvan, betulae cortex dry extract (5–10 : 1); extraction solvent: n-heptane 95% (w/w)) was approved in 2016 for the topical treatment of minor skin wounds in adults. Although its mechanism of action in helping to heal injured skin is not fully understood, birch bark extract appears to stimulate the growth of keratinocytes which then fill the wound.
Saturated fatty acids have no C=C double bonds. They have the formula CH3(CH2)nCOOH, where n is some positive integer. An important saturated fatty acid is stearic acid (n = 16), which when neutralized with sodium hydroxide is the most common form of soap.
As more and more members of Generation Z reached adulthood during the 2020s, voter turnouts in this cohort has been growing, even though young people are still less likely to vote than older generations. In particular, political participation among young women has jumped, breaking a historical trend in which young men were more likely to vote. Living in an age of political polarization has motivated this cohort to participate in the political process. A survey conducted before the 2020 U.S. presidential election by Barnes and Noble Education on 1,500 college students nationwide found that just one third of respondents believe who they vote for is "private information" and three quarters of them find it difficult to find unbiased news sources. 2018 was the first year when the majority of voters aged 18 to 24 were members of Generation Z, and they cast 4% of the votes. During the 2020 U.S. presidential election, Millennials and Generation Z voted for Joe Biden by a margin of 20 percentage points. Generation Z cast 8% of the votes that year. High youth turnout was a factor behind Biden's victory. Yet, young people's support for him fell quickly afterwards. By late 2021, only 29% of adults in this age group approved of his performance as president whereas 50% disapproved, a gap of 21 points, the largest of all age groups. In the 2022 midterm election, voters below the age of 30 were the only major age group supporting the Democratic Party, but their numbers still were large enough to prevent Republicans from controlling the majority of seats in the Senate.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.